Literature DB >> 11340130

Use of filter paper for the collection and analysis of human whole blood specimens.

J V Mei1, J R Alexander, B W Adam, W H Hannon.   

Abstract

The Centers for Disease Control and Prevention and its partners have been operating the Newborn Screening Quality Assurance Program for >20 y. The program helps participating laboratories to evaluate and improve the quality of their newborn-screening testing efforts by providing quality control dried blood spot materials and proficiency-testing materials for the external evaluation of screening programs. The Newborn Screening Quality Assurance Program provides an independent evaluation of filter papers approved by the Food and Drug Administration for the collection of blood for clinical tests. These activities have created a mechanism for the validation of the filter paper blood collection device and the standardization of materials and methods for the analysis of dried blood spots.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340130     DOI: 10.1093/jn/131.5.1631S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  126 in total

1.  Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening.

Authors:  Marie C Earley; Anita Laxova; Philip M Farrell; Rena Driscoll-Dunn; Suzanne Cordovado; Peter J Mogayzel; Michael W Konstan; W Harry Hannon
Journal:  Clin Chim Acta       Date:  2011-04-14       Impact factor: 3.786

2.  Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening.

Authors:  Yijun Li; C Ronald Scott; Nestor A Chamoles; Ahmad Ghavami; B Mario Pinto; Frantisek Turecek; Michael H Gelb
Journal:  Clin Chem       Date:  2004-08-03       Impact factor: 8.327

3.  Commentary on the history and quantitative nature of filter paper used in blood collection devices.

Authors:  Víctor R De Jesús; Donald H Chace
Journal:  Bioanalysis       Date:  2012-03       Impact factor: 2.681

4.  Use of dried blood spots in drug development: pharmacokinetic considerations.

Authors:  Malcolm Rowland; Gary T Emmons
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

5.  Characterization of the elemental composition of newborn blood spots using sector-field inductively coupled plasma-mass spectrometry.

Authors:  Erica K Langer; Kimberly J Johnson; Martin M Shafer; Patrick Gorski; Joel Overdier; Jessica Musselman; Julie A Ross
Journal:  J Expo Sci Environ Epidemiol       Date:  2010-06-30       Impact factor: 5.563

6.  Can finger-prick sampling replace venous sampling to determine the pharmacokinetic profile of oral paracetamol?

Authors:  Baba S Mohammed; Garry A Cameron; Lindsay Cameron; Gabrielle H Hawksworth; Peter J Helms; James S McLay
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

7.  Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory.

Authors:  Janet C Patton; Eveline Akkers; Ashraf H Coovadia; Tammy M Meyers; Wendy S Stevens; Gayle G Sherman
Journal:  Clin Vaccine Immunol       Date:  2006-12-13

8.  Non-derivatized Assay for the Simultaneous Detection of Amino Acids, Acylcarnitines, Succinylacetone, Creatine, and Guanidinoacetic Acid in Dried Blood Spots by Tandem Mass Spectrometry.

Authors:  Carter K Asef; Kameron M Khaksarfard; Víctor R De Jesús
Journal:  Int J Neonatal Screen       Date:  2016-11-24

Review 9.  Blood-borne biomarkers and bioindicators for linking exposure to health effects in environmental health science.

Authors:  M Ariel Geer Wallace; Tzipporah M Kormos; Joachim D Pleil
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2016-10-19       Impact factor: 6.393

10.  C-reactive protein and substance use disorders in adolescence and early adulthood: a prospective analysis.

Authors:  E Jane Costello; William E Copeland; Lilly Shanahan; Carol M Worthman; Adrian Angold
Journal:  Drug Alcohol Depend       Date:  2013-09-10       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.